Drugs / HER2.CAR CMV-specific CTLs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01109095 | Oct 2010 → Jun 2014 | brain glioblastoma | Baylor College of Medicine | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER2.CAR CMV-specific CTLs | “HER2.CAR CMV-specific CTLs will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula.” NCT01109095 ↗ |
| Known as | HER2-CD28 CMV-T cells | “These HER2-CD28 CMV-T cells are an investigational product not approved by the Food and Drug Administration.” NCT01109095 ↗ |
| Action | Deplete | “These chimeric receptor-T cells seem to be able to kill tumors like GBM” NCT01109095 ↗ |
| Modality | Cell therapy | “These HER2-CD28 CMV-T cells are an investigational product not approved by the Food and Drug Administration.” NCT01109095 ↗ |
| Route | Intravenous | “given by intravenous injection” NCT01109095 ↗ |